|Basis of Allotment|
THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE. PURCHASE OR SUBSCRIBE TO SECURITIES.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.
|KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED|
Our Company was incorporated as 'Jagjit Singh and Sons Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, Maharashtra at Mumbai on July 26, 1973. Our Company changed the location of its registered office from the State of Maharashtra to the erstwhile State of Andhra Pradesh, pursuant to an order dated January 29, 2003 by the Company Law Board, Western Region Bench, Mumbai ("Order") and the registration of the Order vide certificate of registration dated February 21, 2003 by the Registrar of Companies, Andhra Pradesh and Telangana (then the Registrar of Companies, Andhra Pradesh) ("RoC"). Subsequently, the name of our Company was changed to 'Krishna Institute of Medical Sciences Private Limited', pursuant to a letter of approval from the Central Government dated January 2, 2004 and a fresh certificate of incorporation issued by the RoC on January 2, 2004. Further ,pursuant to the conversation of our Company to a public limited company, our name was changed to 'Krishna Institute of Medical Sciences Limited' and the RoC issued a fresh certificate of incorporation on January 29, 2004. For further details, see "History and Certain Corporate Matters" on page 198 of the Prospectus dated June 22, 2021 (the "Prospectus').
|Registered and Corporate Office: D No 1-8-31/1, Minister's Road, Secunderabad - 3, Telangana - 500 003, India; Tel: +91 40 4418 6000; Website: www.kimshospitals.com; Contact Person: Umashankar Mantha, Company Secretary and Compliance Officer; E-mail: firstname.lastname@example.org; Corporate Identity Number: U55101TG1973PLC040558|
|OUR PROMOTERS: DR. BHASKARA RAO BOLLINENI, RAJYASRI BOLLINENI, DR. ABHINAY BOLLINENI, ADWIK BOLLINENI AND BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED|
Our Company has filed the Prospectus with the RoC on June 22,2021 and the Equity Shares are proposed to be listed on the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") and the trading will commence on or about June 28,2021.
|BASIS OF ALLOTMENT|
INITIAL PUBLIC OFFERING OF 25,997,133* EQUITY SHARES OF FACE VALUE OF Rs.10 EACH ("EQUITY SHARES") OF KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF Rs.825 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF Rs.815 PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING TO Rs. 21,437.44 MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF 2,436,595* EQUITY SHARES (INCLUDING 254,777* EQUITY SHARES TO BE ISSUED UNDER EMPLOYEE RESERVATION PORTION AT A PRICE OF Rs. 785 AGGREGATING TO Rs. 200.00 MILLION) AGGREGATING TO Rs. 2,000.00 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF 23,560,538 EQUITY SHARES AGGREGATING TO Rs. 19,437.44 MILLION (THE "OFFER FOR SALE") COMPRISING 16,003,615 EQUITY SHARES AGGREGATING TO Rs. 13,202.98 MILLION BY GENERAL ATLANTIC SINGAPORE KH PTE. LTD (THE "INVESTOR SELLING SHAREHOLDER") 387,966 EQUITY SHARES AGGREGATING TO Rs. 320.07 MILLION BY DR. BHASKARA RAO BOLLINENI 775,933 EQUITY SHARES AGGREGATING TO Rs. 640.14 MILLION BY RAJYASRI BOLLINENI 387,966 EQUITY SHARES AGGREGATING TO Rs. 320.07 MILLION BY BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED (COLLECTIVELY THE "PROMOTER SELLING SHAREHOLDERS") 6,005,058 EQUITY SHARES AGGREGATING TO Rs. 4,954.17 MILLION BY PERSONS REFERRED TO IN ANNEXURE A (REFERRED TO AS THE "OTHER SELLING SHAREHOLDERS" TOGETHER WITH THE INVESTOR SELLING SHAREHOLDER AND PROMOTER SELLING SHAREHOLDERS THE "SELLING SHAREHOLDERS" AND SUCH EQUITY SHARES THE "OFFERED SHARES").
* Prior to finalisation of Basis of Allotment.
|OFFER PRICE: Rs. 825 PER EQUITY SHARE OF FACE VALUE OF Rs. 10 EACH EQUITY SHARE|
|ANCHOR INVESTOR OFFER PRICE: Rs. 825 PER EQUITY SHARE|
|THE OFFER PRICE IS 82.5 TIMES THE FACE VALUE|
|Risks to Investors:|
|1.||Average cost of acquisition of Equity Shares held by the Selling Shareholders ranges from Rs. 5.15 per Equity Share to Rs. 360.00 per Equity Share and Offer Price at upper end of the Price Band is Rs. 825.|
|2.||The Price/Earnings ratio based on diluted EPS on a restated consolidated basis for Fiscal 2021 for the Issuer at the upper end of the Price Band is 31.23x. For our peer group, three companies have negative earnings per share for Fiscal 2021 and accordingly the Price/Earnings ratio for them is not applicable. Only one company in the peer group has positive earnings per share and accordingly the Price/Earnings ratio for the respective company is 101.39x for Fiscal 2020.|
|3.||The four book running lead managers ("BRLMs") associated with the Offer have handled 31 public issues in the past three years, out of which 10 issues closed below the issue price on listing date.|
|4.||Weighted Average Return on Net Worth for Fiscals 2021, 2020, 2019 is 16.82%.|
|BID/ OFFER PERIOD:|
|OPENED ON: WEDNESDAY, JUNE 16, 2021|
|CLOSED ON : FRIDAY, JUNE 18, 2021|
|ANCHOR INVESTOR BIDDING DATE WAS :|
|TUESDAY, JUNE 15, 2021|
The Offer was made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations. The Offer was made through the Book Building Process, in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Net Offer was Allotted on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), our Company (through the IPO Committee), in consultation with the Book Running Lead Managers, has allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third was reserved for domestic Mutual Funds, subject to valid Bids having been received from domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Price"). Further, 5% of the Net QIB Portion (excluding the Anchor Investor Portion) was available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion was available for allocation on a proportionate basis to all QIBs (excluding the Anchor Investor Investors), including Mutual Funds, subject to valid Bids having been received at or above the Offer Price. Further, not more than 15% of the Net Offer was available for allocation on a proportionate basis to Non-Institutional Investors and not more than 10% of the Net Offer was available for allocation to RIBs, in accordance with the SEBI ICDR Regulations, subject to valid Bids having been received at or above the Offer Price. Further, Equity Shares were made available for allocation on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids having been received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) were required to mandatorily utilised the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts were blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors were not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 382 of the Prospectus.
The bidding for Anchor Investor opened and closed on June 15, 2021. The Company received 43 applications from 33 Anchor Investors for 12,172,968 Equity Shares. The Anchor Investor Offer Price was finalized at Rs. 825 per Equity Share. A total of 11,584,060 Equity Shares were allocated under the Anchor Investor Portion aggregating to Rs. 10,042,698,600. The Offer (excluding Anchor Investor Portion) received 231,322 applications for 53,701,326 Equity Shares (prior to technical rejections) resulting in 3.7259 times subscription. The details of the applications received in the Offer from various categories are as under (before technical rejections):
|SI. No.||Category||No. of Applications||No. of Equity Shares Applied||Reserved||No. of times Subscribed||Amount (Rs.)|
|A.||Retail Individual Bidders||228,618||5,708,682||2,574,235||2.2176||4,713,086,160|
|B.||Non Institutional Bidders||839||7,078,680||3,861,353||1.8332||5,839,707,384|
|C.||Qualified Institutional Bidders (excluding Anchor Investors)||63||40,647,888||7,722,708||5.2634||33,534,507,600|
|E||Eligible Employees Reservation||1,802||266,076||254,777||1.0443||208,869,768|
A summary of the final demand as per the BSE and NSE as on the Bid/Offer Closing Date at different Bid prices is asunder:
|SI. No.||Bid Price||Bids Quantity||(%) to Total||Cumulative Total||% Cumulative to Total|
The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being the BSE on June 23,2021.
A. Allotment to Retail Individual Bidders (after technical rejections) (including ASBA Applications)
The Basis of Allotment to the Retail Individual Bidders, who have Bid at the Cut-Off Price or at the Offer Price of Rs. 825 per Equity Share, was finalized in consultation with the BSE. This category has been subscribed to the extent of 2.1240 times. The total number of Equity Shares Allotted in Retail Portion is 2,578,337 Equity Shares to 143,240 successful Retail Individual Bidder. The category-wise details of the Basis of Allotment are as under:
|Category||No. of Applications Received||%of Total||Total No. of Equity Shares Applied||% to Total||No. of Equity Shares allotted per Bidder||Ratio||Total No. of Equity Shares Allotted|
|16983 Allottees from Serial no 2 to 13 Additional 1(one) share||17:16983||17|
B. Allotment to Non-Institutional Bidders (after technical rejections)
The Basis of Allotment to the Non-Institutional Bidders, who have Bid at the Offer Price of Rs. 825 per Equity Share or above, was finalized in consultation with the BSE. The Non-Institutional Portion has been subscribed to the extent of 1.8084 times. The total number of Equity Shares Allotted in this category is 3867506 Equity Shares to 786 successful Non-Institutional Bidder. The category-wise details of the Basis of Allotment are as under: (Sample)
|Category||No. of Applications Received||%of Total||Total No. of Equity Shares Applied||% to Total||No. of Equity Shares allotted per a Bidder||Ratio||Total No. of Equity Shares Allotted|
C. Allotment to QIBs (Excluding Anchor Investors) (after technical rejections)
Allotment to QIBs, who have Bid at the Offer Price of Rs. 825 per Equity Share or above, has been done on a proportionate basis in consultation with the BSE. This category has been subscribed to the extent of 5.2634 times of Net QIB Portion. As per the SEBI ICDR Regulations, Mutual Funds were Allotted 5% of the Equity Shares of Net QIB Portion available i.e. 387,674 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were Allotted the remaining available Equity Shares i.e. 7,365,803 Equity Shares on a proportionate basis. The total number of Equity Shares Allotted in the QIB Portion is 7,753,477 Equity Shares, which were allotted to 63 successful QIB Bidders.
The category-wise details of the Basis of Allotment are as under:
D. Allotment to Anchor Investors
The Company and the Promoter Selling Shareholder, in consultation with the BRLMs, have allocated 11,584,060 Equity Shares to 33 Anchor Investors (through 43 applications) at the Anchor Investor Offer Price of Rs. 825 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion.
E. Allotment under Employee Reservation Portion (after technical rejections)
The Basis of Allotment to investors under the Employee Reservation Portion, who have Bid at the Cut-off or the Offer Price of Rs. 825 (including discount of Rs. 40 per Equity Share offered to Eligible Employees) per Equity Share, was finalized in consultation with the BSE. This category has been subscribed to the extent of 0.8308 times. The total number of Equity Shares Allotted in this category is 211,662 Equity Shares to 590 successful Eligible Employees under the Employee Reservation Portion.
The category-wise details of the Basis of Allotment for Employee are as under:
|Category||No. of Applications Received||% of Total||Total No. of Equity Shares Applied||% to Total||No. of Equity Shares allotted per Bidder||Ratio||Total No. of Equity Shares Allotted|
The under-subscribed portion of 41,024 Equity Shares in the Employee Category has been spilled over to QIBs Non- Institutional Investors and Retail Individual Investors in the ratio of 75:15:10 i.e. 30,769 Equity Shares for QIBs 6,153 Equity Shares for Non-Institutional Investors and 4,102 Equity Shares for Retail Individual Investors.
The Board of Directors of our Company on June 24, 2021 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being BSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum-Intimations and/ or notices will be dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Public Offer Account have been issued on June 23, 2021 and payment to non-Syndicate brokers have been issued on June 24, 2021. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on June 24, 2021 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company has filed the listing application with NSE and BSE on June 25, 2021. The Company has received listing and trading approval from NSE and BSE and the trading is expected to commence on June 28, 2021.
All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.
INVESTORS PLEASE NOTE
The details of the allotment made will be hosted on the website of the Registrar to the Offer, Link Intime India Private Limited at www.linkintime.co.in
All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the first/ sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:
|Link Intime India Private Limited|
|C-101, 247 Park, LBS Marg, Vikhroli (West)|
|Mumbai - 400 083, Maharashtra, India|
|Tel: +91 22 4918 6200|
|Investor grievance ID: email@example.com|
|Contact Person: Shanti Gopalkrishnan|
|SEBI Registration Number: INR000004058|
|For KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED|
|On behalf of the Board of Directors|
|Date: June 25, 2021||Company Secretary and Compliance Officer|
THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED.
The Prospectus shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs i.e. Kotak Mahindra Capital Company Limited, Axis Capital Limited, Credit Suisse Securities (India) Private Limited and IIFL Securities Limited at www.investmentbank.kotak.com, www.axiscapital.co.in, https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html and www.iiflcap.com, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 27 of the Prospectus.
This advertisement is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Krishna Institute of Medical Sciences Limited does not intend to register any part of the offering of securities in the United States or to conduct a public offering of securities in the United States.